Kirtland Hills Capital Management LLC Takes Position in Stryker Corporation $SYK

Key Points

• Kirtland Hills Capital Management initiated a position in Stryker, purchasing 3,191 shares valued at approximately $1.005 million. Hedge funds and other institutional investors collectively own 77.09% of the company.
• Stryker reported stronger-than-expected quarterly results, with earnings of $3.69 per share and revenue of $6.59 billion, up 9.4% year over year. The company maintained fiscal 2026 earnings guidance of $14.95–$15.10 per share and declared a quarterly dividend of $0.88.
• Insiders have sold substantial holdings, including Director Ronda E. Stryker’s 50,000-share sale for about $17 million, while insiders sold $216.2 million of stock over the past 90 days. Analysts remain broadly positive with a “Moderate Buy” consensus, though several firms have recently reduced their price targets.

Kirtland Hills Capital Management LLC acquired a new position in Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,191 shares of the medical technology company's stock, valued at approximately $1,005,000.

A number of other hedge funds have also bought and sold shares of the business. VanderPol Investments L.L.C. raised its stake in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC increased its position in shares of Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after buying an additional 28 shares during the period. Rossby Financial LCC lifted its holdings in shares of Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock worth $159,000 after buying an additional 28 shares in the last quarter. Tcfg Wealth Management LLC boosted its position in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock valued at $403,000 after acquiring an additional 29 shares during the period. Finally, ICW Investment Advisors LLC boosted its position in shares of Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company's stock valued at $1,791,000 after acquiring an additional 30 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, insider Debra King sold 826 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company's stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 665,370 shares of company stock worth $216,238,501. 4.60% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of Stryker stock opened at $329.86 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The business's 50-day moving average price is $326.99 and its 200-day moving average price is $332.64. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker's dividend payout ratio (DPR) is 36.48%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Needham & Company LLC decreased their target price on shares of Stryker from $454.00 to $418.00 and set a "buy" rating on the stock in a report on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. JPMorgan Chase & Co. reduced their price target on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Citizens Jmp lowered their price objective on Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a research report on Monday, August 3rd. Finally, Leerink Partners dropped their price objective on Stryker from $410.00 to $407.00 and set an "outperform" rating for the company in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source